

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Microorganisms-based monodisperse microcapsules: encapsulation**
2 **of the fungicide tebuconazole and its controlled release properties**

3

4 *Bo Zhang,^a Teng Zhang,^b Quanxi Wang^b and Tianrui Ren^{*b}*

5

6 *^a State Key Laboratory Breeding Base of Green Pesticide and Agricultural*

7 *Bioengineering/ Key Laboratory of Green Pesticide and Agricultural*

8 *Bioengineering, Ministry of Education, Guizhou University, Guiyang, 550025, P. R.*

9 *China*

10 *^bThe Key Laboratory of Resource Chemistry of Ministry of Education, The*

11 *development centre of plant germplasm resources, College of Life*

12 *and Environmental science, Shanghai Normal University, 100 Guilin Road,*

13 *Shanghai, 200234, P. R. China*

14

15

16

17

18 ** Corresponding author: Prof. Tianrui Ren*

19 *Phone: +86 21 64328850; Fax: +86 21 64328850*

20 *E-mail address: trren@shnu.edu.cn*

21

22

23 **Abstract:** The design of an ideal monodisperse microcapsulation system, which could
24 meet the need for prolonged and better control of drug administration, is a great
25 challenge. Herein cyanobacteria cells served as a natural environmentally-friendly
26 wall material to encapsulate the fungicide tebuconazole (TEB), and then
27 urea-formaldehyde (UF) resins were automatically coated on it via electrostatic
28 interactions. By this means, monodisperse TEB-PCC@UF microcapsules were
29 achieved, which not only can effectively control the drug release rate but also depress
30 the initial “burst effect” to some degree. A bioactivity experiment showed that
31 TEB-PCC@UF microcapsules authentically prolonged the antifungal effects, and
32 were very efficacious in controlling wheat powdery mildew compared with the
33 commercial formulation.

34

35 **Keywords:**

36 Microencapsulation, cyanobacteria, electrostatic interactions, tebuconazole; wheat
37 powdery mildew.

38

39

40

41

42

43

44

45 Introduction

46 Wheat is the most widely cultivated and important food crop in the world as staple
47 crop for about 35% of the human population.¹ Wheat powdery mildew, caused by
48 *Blumeria graminis* f. sp. *Tritici*, has been recognized as the main and widespread
49 disease of wheat in the growing areas leading to significant yield decrease and
50 economic loss worldwide.²⁻⁴ The use of pesticides is essential for preventing and
51 controlling it. Tebuconazole (TEB) as a broad-spectrum, high-efficiency, and
52 low-toxicity triazole systemic fungicide is effective against rust, powdery mildew, net
53 blotch, root rot, scab, smut and seed-borne diseases on a variety of cereal crops.⁵ The
54 most common formulations of TEB are emulsifiable concentrates and wettable
55 powders due to its inferior water-solubility (0.032 g/L at 20 °C). There are still serious
56 problems in these formulations due to the immediate release of the active ingredients,
57 which greatly reduce TEB efficacy. Therefore, excessive quantities of TEB are needed
58 to compensate such losses, also resulting in a severe economic loss. Meanwhile, it is
59 harmful to human health as well as the environment. Thus, how to enhance the
60 efficacy of TEB and minimize its environmental impacts is always an important issue.
61 This problem has stimulated interesting in developing new formulations to improve
62 them. Especially, microencapsulation formulation is one choice for it.

63 Microencapsulation of pesticides is a versatile technology for controlled drug
64 release in which numerous synthetic⁶⁻¹⁰ and natural materials¹¹⁻¹⁷ have been widely
65 employed as pesticide carriers. Many achievements have been made in the field of
66 pesticide encapsulation for controlled release, and encapsulated pesticides have

67 exhibited controlled-release properties, provided enhanced efficacy and reduced the
68 impacts.⁶⁻¹⁷ However, these single-walled microcapsules cannot control the release of
69 the core materials effectively, and lead to high initial burst release because they were
70 often made of thin polymeric membranes. The double-walled microspheres with a
71 drug-encapsulating particle core surrounded by a drug-free shell layer,¹⁸ often exhibit
72 a reduction in the initial burst release and better controlled release properties¹⁹⁻²² as
73 compared to single-walled ones.

74 Microorganisms such as yeast can be harnessed as biocompatible and
75 biodegradable reservoirs and have been successfully applied in the encapsulation of
76 essential oil,²³ flavor,^{24,25} antioxidant^{26,27} and pharmaceuticals.²⁸⁻³⁰ The cell wall and
77 the plasma membrane of the yeast cell make them an attractive encapsulation
78 matrix.³¹ Prokaryotes, unicellular cyanobacteria have unique highly differentiated
79 internal membrane systems. Like other Gram-negative bacteria, cyanobacteria such as
80 *Synechocystis sp. strain PCC 6803* (PCC) have a cell envelope consisting of a plasma
81 membrane, peptidoglycan layer, and outer membrane,³² thus making them an ideal
82 microencapsulation wall material.

83 Urea-formaldehyde (UF) resins via in situ polymerization, in which the capsule
84 wall is formed by condensation polymerization on the phase interface, have been
85 employed as the capsule wall, and attracted attention due to its simplicity, low cost
86 and excellent mechanical strength of the resulting capsules.³³⁻³⁶ In situ polymerization
87 has many advantages, such as feasible size controllability and adjustable shell
88 thickness.

89 Herein, we report a controlled drug-delivery system based on UF modified PCC
90 cells in which TEB are loaded into algae cells. In addition, the uncoated algae cells
91 drug-release system was used for comparison to investigate the release property.
92 Specifically, PCC cells used in this work as appropriate candidates for TEB release
93 system have three distinguishing features: (i) Their surface is negatively charged, so
94 they could adsorb and take up positively charged UF prepolymers via electrostatic
95 interactions in acidic solution. (ii) The groups on cell wall are mainly carboxyl,
96 hydroxyl and amine, which are responsible for hydrogen bond formation with TEB.
97 (iii) They are essentially spherical and exhibit narrow size distribution. The uniform
98 property of PCC enables them to be an intelligent drug delivery systems to develop
99 monodispersed microcapsules, which are critical for the precise manipulation of the
100 loading levels and the release kinetics of encapsulated substances.³⁷

101 **Experimental**

102 **Materials**

103 Technical grade tebuconazole (98.5% purity) was kindly supplied by Jiannong
104 jiangsu Agrochemical & Chemical Co. Ltd. (China). Tebuconazole (45%, WP,
105 Elite) was obtained from Bayer Co. (Kansas City Mo.). Isopropanol (99.5%),
106 formaldehyde (37%), urea and triethanolamine were obtained from Sinopharm
107 Chemical Regent Co. (China). PCC cells were obtained from the Department of
108 Biology, Shanghai Normal University (China). Double distilled water was used in the
109 experiment. All chemicals were analytic grade and were used without further
110 purification.

111 **Fabrication of TEB-PCC**

112 Cyanobacteria used in the experiments were *Synechocystis* sp. strain PCC 6803
113 (PCC). The PCC cells were centrifuged, washed with deionized water 3 times, and
114 spray dried at 220 °C. The dried cells (1.0 g), TEB (0.2 g) and absolute ethanol (400
115 mL) were added into 500 mL capped erlenmeyer flasks under continuous shaking for
116 24 h at 30 °C. Then, the cells were centrifuged for 1 min at 10000 rpm, quickly
117 washed three times with small amounts of absolute ethanol-water mixture (5:95, v/v)
118 and freeze dried for 48 h. The TEB-PCC was obtained.

119 **Preparation of Urea-formaldehyde Pre-polymer**

120 Recrystallized urea (120 g) and 37% formaldehyde solution (225 mL) were mixed
121 in a 250 mL three-neck round-bottomed flask equipped with a mechanical stirrer at
122 room temperature. When urea was dissolved, the pH value of the resultant solution
123 was adjusted to 8~9 by adding suitable amount of triethanolamine, then the solution
124 was gradually heated to 70 °C and maintained at that temperature for 1 h. At the end
125 of the reaction, this urea-formaldehyde pre-polymer resin was cooled and diluted with
126 distilled water to be 500 mL of UF resin solution. The resin concentration was 0.42 g
127 mL⁻¹.

128 **Fabrication of TEB-PCC@UF**

129 TEB-PCC (4 g), prepolymer solution (1 g) and double-distilled water (5.0 mL)
130 were mixed by stirring at 200 rpm at 60 °C, and the pH of the mixture was adjusted to
131 1.5~2 with 1% HCl solution. The reaction was continued with a stirring rate of 500
132 rpm for 4 h. After 4 h, the urea-formaldehyde polymer network is formed at the

133 TEB-PCC interface. The resultant microcapsules were filtered and washed with
134 distilled water for three times and dried in a vacuum oven for 20 h.

135 **In Vitro Drug-release Study**

136 The different TEB samples containing about 20 mg of TEB were weighted and
137 dispersed in 200 mL of ethanol-water mixture (50:50, v/v) with shaking at 100 rpm,
138 25 °C, which was used as the release medium in order to dissolve TEB. 2.0 mL of the
139 suspension was removed for analysis at given time intervals with a syringe followed
140 by 10 min centrifugation at 10000 rpm. The precipitates from centrifugation and the
141 same volume of fresh release medium were returned to the flasks to keep the
142 composition of suspension unchanged. The extracted medium was sufficiently diluted
143 with release medium, and analyzed by UV/Vis spectroscopy at a wavelength of 220
144 nm. Blanks containing no TEB and three replicates of each sample were used for each
145 series of experiments.

146 **Bioassay Experiments**

147 The bioactivities of TEB-PCC@UF and commercial formulations of TEB on wheat
148 powdery mildew which is one of main wheat diseases were conducted on 2-3 leaf
149 stage of wheat seedlings. Two formulations were dissolved in water to prepare 100
150 mg/L of the mother liquors and then diluted into 2.5 ppm, 5 ppm, 10 ppm, 20 ppm, 30
151 ppm and 40 ppm TEB with 0.1% (w/w) Tween 80 solution. The plants were treated
152 homogeneously in a spraying cabin with the pesticides 24 h, 48 h, and 72 h before
153 pathogen inoculation. Wheat was inoculated with pathogens *Erysiphe graminis* (by
154 shaking spore powder over the uninfected plants), and grown in a greenhouse under

155 conditions of 18 °C, at 70% relative humidity, with 12 h light and were used for
156 testing after 4, 8 and 12 days, respectively.

157 **Characterization**

158 The morphology of the samples was characterized by field emission scanning
159 microscopy (FESEM, Hitachi S-4800). Particle size and zeta potential were measured
160 using a Zetasizer Nano-ZS-90 (Malvern Instruments). Fourier transform infrared
161 (FT-IR) spectra were recorded with a Nicolet Magna 550 spectrometer using KBr
162 method. The concentrations of TEB in the adsorption and release experiments were
163 determined by UV-vis spectrophotometer (UV-2000, UNICO (Shanghai) Instruments
164 Co., Ltd.).

165 **Results and discussion**

166 **Characterization of microcapsules**

167 Scheme 1 schematically illustrates the reduction of initial burst and improvement of
168 efficacy on target fungicide of two drug-delivery systems, TEB-PCC@UF and
169 TEB-PCC. In the former one, TEB release is doubly controlled by the PCC cell shell
170 and the UF layer sequentially. The double-walled TEB-PCC@UF system can exhibit
171 a reduction in the initial burst release and better controlled release properties. For the
172 TEB-PCC, the PCC cell shell can control the drug diffusion with sustained-release
173 behavior only.

174 For the TEB-PCC@UF, the TEB-PCC spheres were effectively covered with UF
175 due to the electrostatic interaction. As shown in Figure S1, the Zeta potential of
176 TEB-PCC spheres, UF prepolymers, and TEB-PCC@UF were -40.2 mv, 4.32 mv, and

177 -3.98 mV, respectively, indicating that the TEB-PCC spheres have been successfully
178 coated with UF.

179 The FT-IR spectrum (Figure 1) was employed to further prove the presence of UF
180 on TEB-PCC spheres surface. As shown in Figure 1d and 1e, the FT-IR spectra of UF
181 resins and TEB-PCC@UF closely match to the characteristic peaks of the N-H
182 stretching vibration at 1543cm^{-1} , C=O stretching vibration at 1650cm^{-1} , and a C-H
183 stretching vibration at 1389cm^{-1} . The peaks at 1242cm^{-1} and 3357cm^{-1} are assigned
184 to stretching vibrations of C-N bonds, and O-H bonds, respectively. This indicates that
185 the UF resin shell was formed on the surface of TEB-PCC. Furthermore, it is
186 noteworthy to mention that the characteristic adsorption bands of PCC (Figure 1a) and
187 TEB (Figure 1b) were not observed at TEB-PCC@UF (Figure 1e) due to the sealing
188 and penetration resistance of the UF shell resins fully filled with TEB-PCC.^{33,38,39}

189 The FT-IR spectrum of the TEB-PCC systems was similar to the spectrum of the
190 PCC cells (Figure 1a and 1c), whilst the IR absorption bands of TEB significantly
191 decreased, nearly disappeared. This observation suggests that the main bands of TEB
192 was 'hidden' by the interaction with the inner wall groups of PCC cell components
193 and TEB molecules are rather located inside the PCC cells. The above results
194 correlate well with Shi and Paramera's²⁶⁻²⁸ in which the encapsulation of resveratrol,
195 chlorogenic acid and curcumin in yeast cells was studied respectively, and the
196 disappearance of the characteristic IR absorption bands of the substances in the
197 microcapsules was attributed to the encapsulation into cells.

198 FESEM and dynamic light scattering (DLS) revealed that PCC cells were almost

199 monodisperse microspheres (Figure 2a) and the average diameter of PCC is relatively
200 uniform (1.474 μm , Figure S2 in the Supporting Information). Figure 2b shows a
201 FESEM micrograph of the PCC after adsorption of TEB molecules (TEB-PCC). No
202 apparent difference can be observed compared to Figure 2a, although TEB-PCC
203 contains a large number of TEB molecules. Moreover, the adsorption kinetics studies
204 of TEB onto PCC showed that the absorption equilibrium was achieved after 24 h. As
205 obtained from adsorption isotherms (Figure S3 in the Supporting Information), the
206 maximum adsorbed amount was about 20.1 mg/g at an equilibrium concentration of
207 approximately 500 mg/L. Consequently, the number of TEB molecules encapsulated
208 in PCC cell sphere is 7.99×10^7 (see the Supporting Information S4). From the FESEM
209 images (Figure 2b, c and d), it clearly depicts that TEB-PCC@UF spheres possess a
210 roughly spherical structure with an average diameter of 1.773 μm , which perfectly
211 replicate the morphology of the cells. Meanwhile, a uniform thin layer with a
212 thickness of around 0.15 μm completely covers the whole outer surface of the
213 TEB-PCC microspheres, which correlate well with the normal FT-IR spectra of
214 TEB-PCC@UF.

215 To characterize the sustained-release effect, we systematically investigated the
216 release behavior of TEB from the TEB-PCC and TEB-PCC@UF systems in media of
217 ethanol/water mixture (v/v, 1:1). As shown in Figure 3a, the amounts of released free
218 TEB reach about 94.6% in less than 53 h (Figure 3a), and Figure 3b and 3c clearly
219 presented that both systems exhibit sustained-release properties. The TEB-PCC
220 system takes about 76 h to release 72% of TEB into the solvent, which might be

221 attributed to the fact that the plasma membrane, peptidoglycan layer, and outer
222 membrane of the PCC cells act as effective barriers preventing the premature release
223 of the TEB from TEB-PCC system.^{23,24} In addition, it has been reported⁴⁰⁻⁴² that the
224 hydrogen bonds interaction between the carrier and the active ingredient can also
225 affect the release of active ingredient from the matrix. A high energy of interaction
226 would result in a slower release of the active ingredient. Consequently, a large number
227 of hydroxyl and amine groups on the PCC cell (Figure 1a) act as proton donors for
228 hydrogen bonds, and the nitrogen atoms and hydroxyl groups of TEB act as acceptors.
229 Thus, the hydrogen bond interaction between TEB and the carrier may also contribute
230 to the slow-release of TEB from TEB-PCC system.

231 For the TEB-PCC@UF system, the TEB release time and rate was obviously
232 decreased compared to TEB-PCC. The release amount only reaches 42% after 76 h.
233 This finding indicates that the UF layer plays an important role and serves as an
234 effective diffusion barrier during the controlled-release process. Furthermore, the t_{50}
235 values (the time taken for 50% of the TEB to be released, Table 1) were 12.64 h,
236 34.23 h and 101.62 h for the free TEB, TEB-PCC and TEB-PCC@UF microcapsules,
237 respectively. These results can be concluded that the addition of PCC cells is
238 beneficial to slow down the release of TEB from TEB-PCC microcapsules. Moreover,
239 the TEB-PCC@UF system has a much better controlled drug-release property than
240 the TEB-PCC.

241 The major problem in a controlled release system is the obvious initial burst during
242 which a great amount of drug releases, resulting in an acutely high concentration and

243 release lose control.^{43,44} As shown in Figure 3, there was an initial burst in the release
244 profile of the free TEB, and it was significantly suppressed in the single-walled
245 TEB-PCC and double-walled TEB-PCC@UF systems. Especially in the
246 double-walled TEB-PCC@UF, its initial burst time is the shortest, suggesting that the
247 double-walled encapsulation of TEB not only can prolong the release time but also
248 depress the initial “burst effect” to some degree.

249 **Drug release studies**

250 Finally, the release mechanisms of TEB were investigated for the TEB-PCC and
251 TEB-PCC@UF microcapsules. The release process should involve two steps: i) The
252 bulk solution diffuses into the microcapsules and the core TEB dissolves in it. ii) The
253 dissolved TEB molecules spread out. It is expected that at the early release stage the
254 TEB concentration within the microcapsules is close to saturation, and is sustained
255 until the core TEB dissolve completely.⁴⁵ During this period, the permeability of the
256 microcapsule shell is the determining factor controlling the release rates, explaining
257 why the release rate decreases as the microcapsule wall thickness increases.⁴⁶ Here,
258 we analyzed the kinetic release data of the TEB from microcapsules by applying the
259 empirical equation⁴⁷

$$260 \quad M_t/M_0 = Kt^n \quad (1)$$

261 where M_t/M_0 is the percentage of TEB released at time t , K is a constant that
262 incorporates characteristic of the macromolecular network system and the active
263 ingredient, and n is a diffusional parameter, which is indicative of the transport
264 mechanism. The values of K and n obtained from the initial 60% of TEB released are

265 presented in Table 1. According to correlation coefficients, we can deduce that the
266 release profiles of TEB from single-walled TEB-PCC and double-walled
267 TEB-PCC@UF microcapsules fit well to the empirical equation. The n values are
268 0.387 and 0.536 for TEB-PCC microcapsule and TEB-PCC@UF microcapsule, which
269 are very close to 0.5 reported for the diffusion mechanism of spherical formulations in
270 the ref 47 and 7. For spheres, when corrected for geometry of the device
271 (microparticle), the diffusion parameter changes to a value of 0.43 when Fickian
272 diffusion occurs in a spherical monolithic matrix. Value of n close to 0.43 are
273 indicative of Fickian diffusion.⁴⁷ The larger n (0.536) may be ascribed to the swelling
274 of polymer coated carrier^{42,48} or the interaction between TEB and UF resins induces
275 the deviation from Fickian diffusion.⁴⁹ These results suggested that the release
276 mechanism of TEB from the single or double-walled microcapsules is Fickian
277 diffusion, that is, the release is diffusion-controlled.

278 **Bioassay Experiment**

279 To further evaluate the controlled release properties of the TEB-PCC@UF
280 microcapsules, we assessed its protective and persistent effects against wheat
281 powdery mildew. For the test of protective effects (Figure 4a, b), the plants were
282 inoculated with pathogen of the plant disease for 24 h after spraying with the
283 TEB-PCC@UF microcapsules or the commercial formulation of TEB at doses
284 ranging from 2.5 to 40 mg/L. It was found that the control efficacies of two
285 formulations were increased with the increasing of TEB concentration sampling at the
286 4th, 8th and 12th day after TEB application (Figure 4a, b). However, compared to the

287 commercial formulation, the TEB-PCC@UF microcapsules exhibited excellent
288 control efficacy against wheat powdery mildew, particularly in the concentrations
289 ranging from 10 to 40 mg/L. This suggested that the TEB-PCC@UF microcapsules
290 can provide significantly protection effect on wheat. For example, at 40 mg/L
291 concentration, the control efficacies of TEB-PCC@UF microcapsules at intervals
292 were 95.75%, 88.25% and 83.75%, but that of the commercial product were merely
293 91.00%, 75.25% and 51.00% respectively. The preferable protective effect can be
294 ascribed to the controlled-release ability of the TEB-PCC@UF microcapsules, which
295 evidently improved the long-term bioavailability of TEB.

296 For the test of persistent effects, the plants inoculated for 24, 48, or 72 h after spray
297 different formulations of TEB at the above concentrations was also studied; and the
298 control efficacies were assessed at the 4th, 8th and 12th day after inoculation,
299 respectively (Figure 4). TEB-PCC@UF microcapsules also showed a superior
300 persistent effect due to its advantageous controlled-release property. For example, for
301 the 72 h after TEB application, the TEB-PCC@UF microcapsules, especially at high
302 concentrations, exhibited a good control efficacy in 12 d after inoculation. At 40 mg/L
303 concentration, the control efficacy still reached 80.75% in 12 d after inoculation.
304 However, the control efficacy of the commercial formulation of TEB only reached
305 52.25%. Obviously, the TEB-PCC@UF microcapsules had remarkable advantages in
306 controlling TEB release compared to the commercial formulation of TEB.

307

308

309 **Conclusions**

310 In summary, we have successfully developed an efficient cyanobacteria cells-based
311 controlled drug-release system by using UF as a coating shell to modify TEB-loaded
312 PCC cells. Compared to the TEB-PCC system without UF, the TEB-PCC@UF system
313 not only can effectively control the drug release rate but also depress the initial “burst
314 effect” to some degree. The UF layer plays an important role and serves as an
315 effective diffusion barrier during the controlled-release process. Furthermore, the
316 control efficacy of TEB-PCC@UF system against wheat powdery mildew remained
317 over 80% in 12 d after inoculation, due to the slow and persistent release of the active
318 components from the system. In contrast, the control efficacy of the commercial
319 formulation at the same concentration (40 mg/L) only reached 52.25%. Accordingly,
320 the cyanobacteria cells are a promising drug controlled-release platform.

321

322 **Acknowledgements**

323 We thank the National Natural Science Foundation of China (21172147), the
324 National Key Technology R&D Program of China (2011BAE06B06-4), and the
325 National High Technology Research and Development Program of China (863:
326 2011AA100503).

327

328

329

330

331 **References**

- 332 1 X. Q. Huang and M. S. Roder, *Euphytica*, 2004, **137**, 203-223.
- 333 2 A. K. Sharma, R. K. Sharma and K. S. Babu, *Crop Prot.*, 2004, **23**, 249-253.
- 334 3 R. N. Strange and P. R. Scott, *Annu. Rev., Phytopathol.*, 2005,**40**, 83-116.
- 335 4 C. A. Griffey, M. K. Das and E. L. Stromberg, *Plant Dis.*, 1993, **77**, 618-622.
- 336 5 C. D. S. Tomlin, *The e-Pesticide Manual*, version 2.2., 12th ed., BCPC, Hampshire,
- 337 UK, 2002.
- 338 6 C. C. Dowler, *J. Agric. Food Chem.*, 1999, **47**, 2908-2913.
- 339 7 J. Asrar, Y. Ding, R. E. La Monica and L. C. Ness, *J. Agric. Food Chem.*, 2004, **52**,
- 340 4814-4820.
- 341 8 P. Stloukal, P. Kucharczyk, V. Sedlarik, P. Bazant and M. Koutny, *J. Agric. Food*
- 342 *Chem.*, 2012, **60**, 4111-4119.
- 343 9 S. F. Zhang, P. H. Chen, F. Zhang, Y. F. Yang, D. K. Liu and G. Wu, *J. Agric. Food*
- 344 *Chem.*, 2013, **61**, 12219-12225.
- 345 10 R. Grillo, A. E. S. Pereira, N. F. S. de Melo, R. M. Porto, L. O. Feitosa, P. S.
- 346 Tonello, N. L. D. Filho, A. H. Rosa, R. Lima and L. F. Fraceto, *J. Hazard. Mater.*,
- 347 2011, **186**, 1645-1651.
- 348 11 V. Balmas, G. Delogu, S. Sposito, D. Rau and Q. Migheli, *J. Agric. Food Chem.*,
- 349 2006, **54**, 480-484.
- 350 12 F. Flores-Céspedes, I. Daza-Fernández, M. Villafranca-Sánchez and M.
- 351 Fernández-Pérez, *J. Agric. Food Chem.*, 2009, **57**, 2856-2861.
- 352 13 X. J. Wang and J. Zhao, *J. Agric. Food Chem.*, 2013, **61**, 3789-3796.

- 353 14 D. B. Yang, N. Wang, X. J. Yan, J. Shi, M. Zhang, Z. Y. Wang and H. Z. Yuan,
354 *Colloids and Surfaces B: Biointerfaces*, 2014, **114**, 241-246.
- 355 15 F. J. Garrido-Herrera, I. Daza-Ferández, E. González-Pradas and M.
356 Fernández-Pérez, *J. Hazard. Mater.*, 2009, **168**, 220-225.
- 357 16 B. Singh, D. K. Sharma and A. Gupta, *J. Hazard. Mater.*, 2009, **161**, 208-216.
- 358 17 A. Roy, J. Bajpai and A. K. Bajpai, *Carbohydr. Polym.*, 2009, **76**, 222-231.
- 359 18 K. J. Pekarek, J. S. Jacob and E. Mathiowitz, *Nature*, 1994, **367**, 256-260.
- 360 19 Y. J. Xia, Q. X. Xu, C. H. Wang and D. W. Pack, *J. Pharm. Sci.*, 2013, **102**,
361 1601-1609.
- 362 20 Y. J. Xia, P. F. Ribeiro and D. W. Pack, *J. Control. Release*, 2013, **172**, 707-714.
- 363 21 H. X. Tan and J. D. Ye, *Appl. Surf. Sci.*, 2008, **255**, 353-356.
- 364 22 S. He, W. B. Zhang, D. G. Li, P. L. Li, Y. C. Zhu, M. M. Ao, J. Q. Li and Y. S. Cao,
365 *J. Mater. Chem. B*, 2013, **1**, 1270-1278.
- 366 23 J. R. P. Bishop, G. Nelson and J. Lamb, *J. Microencapsul.*, 1998, **15**, 761-773.
- 367 24 V. Normand, G. Dardelle, P. E. Bouquerand, L. Nicolas and D. Johnston, *J. Agric.*
368 *Food Chem.*, 2005, **53**, 7532-7543.
- 369 25 G. Dardelle, V. Normand, M. Steenhoudt, P. E. Bouquerand, M. Chevalier and P.
370 Baumgartner, *Food Hydrocolloids*, 2007, **21**, 953-960.
- 371 26 G. R. Shi, L. Q. Rao, H. Z. Yu, H. Xiang, G. P. Pen, S. Long and C. Yang, *J. Food*
372 *Eng.* 2007, **80**, 1060-1067.
- 373 27 G. R. Shi, L. Q. Rao, H. Z. Yu, H. Xiang, H. Yang and R. Ji, *Int. J. Pharm.*, 2008,
374 **349**, 83-93.

- 375 28 E. I. Paramera, S. J. Konteles and V. T. Karathanos, *Food Chem.*, 2011, **125**,
376 892-902.
- 377 29 S. Blanquet, G. Garrait, E. Beyssac, C. Perrier, S. Denis, G. Hebrard and M. Alric,
378 *Eur. J. Pharm. Biopharm.*, 2005, **61**, 32-39.
- 379 30 S. Blanquet, S. Marol-Bonnin, E. Beyssac, D. Pompon, M. Renaud and M. Alric,
380 *Trends Biotechnol.*, 2001, **19**, 393-400.
- 381 31 P. N. Lipke and R. Ovalle, *J. Bacteriol.*, 1998, **180**, 3735-3740.
- 382 32 E. Hoiczky and A. Hansel, *J. Bacteriol.*, 2000, **182**, 1191-1199.
- 383 33 R. Qin, G. Y. Xu, L. Guo, Y. Jiang and R. Y. Ding, *Mater. Chem. Phys.*, 2012, **136**,
384 737-743.
- 385 34 J. P. Wang, X. P. Zhao, H. L. Guo and Q. Zheng, *Langmuir*, 2004, **20**,
386 10845-10850.
- 387 35 S. Cosco, V. Ambrogi, P. Musto and C. Carfagna, *J. Appl. Polym. Sci.*, 2007, **105**,
388 1400-1411.
- 389 36 L. Yuan, F. Chen, A. J. Gu, G. Z. Liang, C. Lin, S. D. Huang, S. Nutt, G. Q. Chen
390 and Y. M. Gao, *Polym. Bull.*, 2014, **71**, 261-273.
- 391 37 L. Y. Chu, A. S. Utada, R. K. Shah, J. W. Kim and D. A. Weitz, *Angew. Chem. Int.*
392 *Ed.*, 2007, **46**, 8970-8974.
- 393 38 S. J. Park, Y. S. Shin and J. R. Lee, *J. Colloid Interface Sci.*, 2001, **241**, 502-508.
- 394 39 H. L. Guo and X. P. Zhao, *Opt. Mater.*, 2004, **26**, 297-300.
- 395 40 J. V. Cottefill, R. M. Wilkins and F. T. da Silva, *J. Control. Release*, 1996, **40**,
396 133-142.

- 397 41 Y. Yi, S. Xu, H. K. Sun, D. Chang, Y. H. Yin, H. Zheng, H. X. Xu and Y. C. Lou,
398 *Carbohydr. Polym.*, 2011, **86**, 1007-1013.
- 399 42 J. Li, Y. Li and H. Dong, *J. Agric. Food Chem.*, 2008, **56**, 1336-1342.
- 400 43 C. D. Herzfeldt and R. Kuemmel, *Drug Dev. Ind. Pharm.*, 1983, **9**, 767-793.
- 401 44 L. Vayssieres, C. Chaneac, E. Tronc and J. P. Jolivet, *J. Colloid Interface Sci.*, 1998,
402 **205**, 205-212.
- 403 45 A. A. Antipov, G. B. Sukhorukov, E. Donath and H. Moehwald, *J. Phys. Chem. B*,
404 2001, **105**, 2281-2284.
- 405 46 X. Qiu, S. Leporatti, E. Donath, H. Moehwald, *Langmuir*, 2001, **17**, 5375-5380.
- 406 47 P. L. Ritger and N. A. Peppas, *J. Control. Release*, 1987, **5**, 23-36.
- 407 48 P. L. Ritger and N. A. Peppas, *J. Control. Release*, 1987, **5**, 37-42.
- 408 49 S. Conti, L. Maggi, L. Segale, E. Ochoa Machiste, U. Conte, P. Grenier and G.
409 Vergnault, *Int. J. Pharm.*, 2007, **333**, 143-151.
- 410
- 411
- 412
- 413
- 414
- 415
- 416
- 417
- 418

419 **List of Figure Legends**

420 **Fig. 1** FT-IR spectra of (a) PCC, (b) TEB, (c) TEB-PCC, (d) UF resins, and (e)

421 TEB-PCC@UF.

422 **Fig. 2** FESEM micrographs of PCC (a), the TEB-PCC system (b), and the

423 TEB-PCC@UF system (c and d)

424 **Fig. 3** Release profiles of TEB from the free TEB (a), the TEB-PCC system (b), and

425 the TEB-PCC@UF system (c) in ethanol/water mixture (v/v, 1:1).

426 **Fig. 4** Control efficacy of TEB-PCC@UF microcapsules (a, c and e) and commercial

427 formulation (b, d and f) on wheat powdery mildew after 4, 8 and 12 day sprayed

428 wheat at 24 h (a, b), 48 h (c, d) and 72 h (e, f) before inoculation, respectively.

429 **Scheme 1.** Schematic illustration of two drug-delivery systems which show different

430 controlled-release patterns.

431

432 **List of Table Titles**

433 **Table 1:** Characteristic parameters of TEB-loaded microcapsules

434

435

436

437


438

439

440

441 **Figures**

442



443

444 **Fig.1** FT-IR spectra of PCC (a), TEB (b), TEB-PCC (c), UF resins (d), and

445 TEB-PCC@UF (e).

446

447

448

449

450

451

452

453

454

455

456

457

458

459


460

461

462

463

464



465 **Fig. 2** FESEM micrographs of PCC (a), the TEB-PCC system (b), and the

466 TEB-PCC@UF system (c and d).

467

468

469

470

471

472


473

474

475

476

477



478

479 **Fig. 3** Release profiles of TEB from the free TEB (a), the TEB-PCC system (b), and
480 the TEB-PCC@UF system (c) in ethanol/water mixture (v/v, 1:1). (Error bars
481 represent the standard deviation of three replicates. Where error bars are not shown,
482 the values of standard deviation are smaller than the data points.).

483

484

485

486


487

488

489

490

491




492

493 **Fig. 4** Control efficacy of TEB-PCC@UF microcapsules (a, c and e) and commercial

494 formulation (b, d and f) on wheat powdery mildew after 4, 8 and 12 day sprayed

495 wheat at 24 h (a, b), 48 h (c, d) and 72 h (e, f) before inoculation, respectively.

496



497

498 **Scheme 1.** Schematic illustration of two drug-delivery systems which show different

499 controlled-release patterns.

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515 **Tables**

516

517 **Table 1** Characteristic parameters of TEB-loaded microcapsules

Sample	K (h ⁻¹) ^[a]	n ^[b]	R^2 ^[c]	t_{50} (h) ^[d]
TEB-PCC	14.160±1.984	0.387±0.029	0.926	34.23
TEB-PCC@UF	3.778±0.661	0.536±0.034	0.980	101.62

518 [a] K is the constant that incorporates the matrix properties. [b] n is a diffusion parameter. [c] R 519 is a correlation coefficient. [d] t_{50} is the time it takes to release 50% of TEB.

520

521

522

523

524

525

526

527

528

529

530

531

532